Signature
/s/Christopher Anzalone
Issuer symbol
ARWR
Transactions as of
09 Apr 2025
Net transactions value
-$1,533,337
Form type
4
Filing time
11 Apr 2025, 18:20:07 UTC
Previous filing
17 Mar 2025
Next filing
16 Dec 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale $350,579 -35,305 -0.87% $9.93 4,027,072 09 Apr 2025 Direct F1, F2, F3
transaction ARWR Common Stock Sale $36,550 -3,400 -0.08% $10.75 4,023,672 09 Apr 2025 Direct F1, F3, F4
transaction ARWR Common Stock Sale $19,016 -1,617 -0.04% $11.76 4,022,055 09 Apr 2025 Direct F1, F3, F5
transaction ARWR Common Stock Sale $543,500 -50,000 -1.2% $10.87 3,972,055 10 Apr 2025 Direct F1, F3
transaction ARWR Common Stock Sale $583,692 -50,800 -1.3% $11.49 3,921,255 11 Apr 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of securities to cover taxes associated with the vesting of restricted stock awards
F2 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 9.67 to $ 10.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F4 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 10.51 to $ 11.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 11.49 to $ 12.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.